MAM
Kshema General Insurance launches campaign to raise awareness about crop insurance
Mumbai: Kshema General Insurance Ltd has announced the launch of its national marketing campaign aimed at raising awareness about crop insurance to coincide with the beginning of the Kharif season. The centrepiece of the 360-degree campaign is a TVC which will reach farmers as they start sowing with the onset of the monsoons. The TV campaign will be further augmented by a concurrent campaign in print, digital, and outdoor media. The campaign highlights the importance of crop insurance in creating a financial safety net for farmers when extreme climate events are becoming more frequent and intense.
The 30-second TVC was developed in-house to forge a deeper connection with farmers, and easy accessibility of Kshema’s industry-first crop insurance plan Sukriti along with Prakriti. The product is available on Kshema’s proprietary platform which can be downloaded from Google Playstore. Any farmer or family member with insurable income can buy this customisable crop insurance starting from Rs 499 per acre and protect more than 100 crops from a combination of one major and one minor peril. All they need to do is download the app, register, geo-tag their farm and pay the premium.
Commenting on the launch of the TVC, Kshema General Insurance Ltd CMO Bhaskar Thakur said, “I am pleased that we relied on the incredibly powerful imagery of a father-daughter relationship to create awareness about mitigating crop loss and resulting income shock with the help of crop insurance. We chose the emotional depth of the conversation between a father and daughter to convey the importance of protecting farmers from income shocks and building financial resilience. Children can ask the most poignant questions with the utmost simplicity which forces an adult to think. We chose to capture that moment of innocence to carry our message of buying crop insurance to mitigate financial losses caused by perils.”
The film opens with a farmer working in his field who then takes a break to have lunch with his daughter. She innocently asks her father why he needs to work hard. He lovingly explains he works hard so that everyone has food on their table, and they don’t face any trouble. The daughter exclaims proudly he is there to ensure no one is in trouble but asks with concern who will look after him if he faces any adverse situation. The camera pans to the farmer who now looks worried and then cuts to the visual of Kshema app with the narrator explaining that any farmer can buy Sukriti easily via the app.
Kshema’s media partner Mudramax is spearheading the campaign and the TVC will be aired on news, music, movies, and general entertainment channels in the country. “We are thrilled to partner with Kshema General Insurance Limited on this groundbreaking integrated multi-media marketing campaign,” said Mudramax president – integrated media Rammohan Sundaram. “By leveraging a strategic mix of TV, Print, and Digital broadcast properties, including a carefully curated set of influencers, we aim to create a cohesive and immersive brand experience that resonates with the target audiences across all touchpoints. This campaign exemplifies the innovative and collaborative spirit of both our teams, and we are confident it will drive significant engagement and impact”.
The new commercial will also be bolstered by an intensive digital campaign to drive awareness around the critical role played by crop insurance in mitigating risks caused by natural perils.
The agricultural and allied sectors engage the largest share of the workforce, constituting 45.5 per cent as per the Periodic Labour Force Survey of 2021-22, and contribute nearly 15 per cent to India’s GDP. However, natural catastrophic events are becoming more frequent and intense due to climate change affecting the farming community disproportionately. These natural perils cause not only loss of crop but also livelihoods in the worst cases as 85 per cent of farmers have modest annual incomes.
Kshema endeavours to support the farming community through these trying times by providing them tailor-made insurance products after adequately mapping and analysing the risk involved.
Brands
Sun Pharma to acquire Organon in $11.75 billion deal at $14 per share
Acquisition to create $12.4 billion pharma giant with global scale and biosimilars push
MUMBAI: Sun Pharmaceutical Industries Limited has signed a definitive agreement to acquire Organon & Co. in an all-cash deal valued at $11.75 billion, marking one of the largest cross-border pharma acquisitions by an Indian firm.
Under the terms of the agreement, Organon shareholders will receive $14.00 per share in cash, with Sun Pharma set to acquire 100 per cent of the company’s outstanding shares. The transaction, approved by the boards of both companies, is expected to close in early 2027, subject to regulatory approvals and shareholder consent.
The deal significantly expands Sun Pharma’s global footprint and strengthens its position across women’s health, biosimilars, and branded generics. The combined entity is projected to generate revenues of around $12.4 billion, placing it among the top 25 pharmaceutical companies globally.
Organon, which was spun off from Merck in 2021, brings a portfolio of over 70 products spanning women’s health and general medicines, with operations across more than 140 countries. Its established presence in key markets such as the US, Europe, and China complements Sun Pharma’s existing strengths and growth ambitions.
Sun Pharmaceutical Industries Limited executive chairman Dilip Shanghvi said, “This transaction represents a significant opportunity for Sun Pharma to build on its vision of reaching people and touching lives. Organon’s portfolio, capabilities and global reach are highly complementary to our own.”
Sun Pharmaceutical Industries Limited managing director Kirti Ganorkar added, “This transaction is a logical next step in strengthening Sun Pharma’s global business. Together, we will become a partner of choice for acquiring and launching new products.”
From Organon’s side, Organon & Co. executive chair Carrie Cox noted, “This all-cash transaction offers compelling and immediate value to Organon stockholders, while positioning the business for continued growth under Sun Pharma.”
Strategically, the acquisition gives Sun Pharma entry into the global biosimilars space as a top 10 player and strengthens its innovative medicines portfolio, which is expected to contribute around 27 per cent of combined revenues. The deal is also expected to nearly double EBITDA and cash flow, supporting long-term deleveraging and investment capacity.
Sun Pharma plans to fund the acquisition through a mix of internal accruals and committed financing from global banks, while maintaining focus on disciplined integration and operational continuity post-merger.
If completed as planned, the deal signals a clear shift in India’s pharmaceutical ambitions, from scale at home to leadership on the global stage, with Sun Pharma positioning itself as a more diversified and innovation-led healthcare powerhouse.
